

JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Victor Brantl

Serial No: 10/618,148

Filed: July 10, 2003

For: USE OF RIBOFURANOSE
DERIVATIVES AGAINST
INFLAMMATORY BOWEL
DISEASES



Art Unit: 1623

Examiner: Khare, Devesh

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450, on
November 22, 2004

Date of Deposit
Wei-Ning Yang, Reg. No. 38,690
Name
Signature  11/22/2004
Date

**TERMINAL DISCLAIMER TO OBVIATE A
DOUBLE PATENTING REJECTION (37 C.F.R.
§ 1.321(c))**

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

IDENTIFICATION OF PERSON MAKING THIS DISCLAIMER

I, Wei-Ning Yang, represent that I am

an applicant
 an assignee
 a representative authorized to sign on behalf of the assignee identified below owning all of the interest in this application.

The assignee is:

Name of assignee

RIBAPHARM PHARMACEUTICALS

Address of assignee

3300 Hyland Avenue, Costa Mesa, California
92626

Title of disclaimant
authorized to sign on
behalf of assignee

Attorney for Applicant/Patent Owner

RECORDAL OF ASSIGNMENT IN PATENT OFFICE

The assignment was recorded on _____ at
Reel No.
Frame No(s).
 authorization for recordal of the assignment is to follow

EXTENT OF INTEREST

The extent of my (our) interest is in

the whole of this invention
 a sectional interest in this invention as follows:

DISCLAIMER

RIBAPHARM PHARMACEUTICALS hereby disclaims the terminal part of a patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of:

United States Patent No. 6,573,248 and 6,455,508 as presently shortened by any terminal disclaimer
 any patent granted on Application Serial No. _____

and hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

United States Patent No. 6,573,248 and 6,455,508.
 any patent granted on Application Serial No. _____

this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

RIBAPHARM PHARMACEUTICALS does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of

United States Patent No. 6,573,248 and 6,455,508 as presently shortened by any terminal disclaimer

any patent granted on Application Serial No. _____

in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

FEE STATUS
(37 C.F.R. § 1.20(d))

Other than small entity

Small entity

verified statement attached

verified statement filed _____

FEE PAYMENT

Attached is a check in the sum of \$_____.


If it should be determined that for any reason either an insufficient fee or an excessive fee has been paid, please charge any insufficiency or credit any overpayment necessary to ensure consideration of the information disclosure statement for the above-identified application to Deposit Account No. 50-1314. A copy of this petition is enclosed.

Charge Account No. 50-1314 the sum of \$110.00. A duplicate of this disclaimer is attached.

Undersigned further declares that the evidentiary documents establishing ownership by the assignee have been reviewed and certifies that to the best of assignee's knowledge and belief, title is in the assignee seeking to take this action.

Undersigned further declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: November 22, 2004

By: 

Wei-Ning Yang
Reg. No. 38,690
Attorney for Applicant and Assignee

HOGAN & HARTSON L.L.P.
Biltmore Tower
500 South Grand Avenue, Suite 1900
Los Angeles, CA 90071
Telephone: (213) 337-6700
Facsimile: (213) 337-6701

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Victor Brantl

Serial No: 10/618,148

Filed: July 10, 2003

For: USE OF RIBOFURANOSE
DERIVATIVES AGAINST
INFLAMMATORY BOWEL
DISEASES**TERMINAL DISCLAIMER TO OBLIGATE A
DOUBLE PATENTING REJECTION (37 C.F.R.
§ 1.321(c))**Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

IDENTIFICATION OF PERSON MAKING THIS DISCLAIMER

I, Wei-Ning Yang, represent that I am

an applicant
 an assignee

XX a representative authorized to sign on behalf of the assignee identified below owning all of the interest in this application.

The assignee is:


Name of assignee

RIBAPHARM PHARMACEUTICALS

Address of assignee

3300 Hyland Avenue, Costa Mesa, California
92626Title of disclaimant
authorized to sign on
behalf of assignee

Attorney for Applicant/Patent Owner

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:	
Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on	
November 22, 2004	
Date of Deposit	
Wei-Ning Yang, Reg. No. 38,690	
Name	
	11/22/2004
Signature	Date

RECORDAL OF ASSIGNMENT IN PATENT OFFICE

The assignment was recorded on _____ at
Reel No.
Frame No(s).
 authorization for recordal of the assignment is to follow

EXTENT OF INTEREST

The extent of my (our) interest is in

the whole of this invention
 a sectional interest in this invention as follows:

DISCLAIMER

RIBAPHARM PHARMACEUTICALS hereby disclaims the terminal part of a patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of:

United States Patent No. 6,573,248 and 6,455,508 as presently shortened by any terminal disclaimer
 any patent granted on Application Serial No. _____

and hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

United States Patent No. 6,573,248 and 6,455,508.
 any patent granted on Application Serial No. _____

this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

RIBAPHARM PHARMACEUTICALS does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of

United States Patent No. 6,573,248 and 6,455,508 as presently shortened by any terminal disclaimer

any patent granted on Application Serial No. _____

in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

FEE STATUS
(37 C.F.R. § 1.20(d))

Other than small entity

Small entity

verified statement attached

verified statement filed _____

FEE PAYMENT

Attached is a check in the sum of \$_____.


If it should be determined that for any reason either an insufficient fee or an excessive fee has been paid, please charge any insufficiency or credit any overpayment necessary to ensure consideration of the information disclosure statement for the above-identified application to Deposit Account No. 50-1314. A copy of this petition is enclosed.

Charge Account No. 50-1314 the sum of \$110.00. A duplicate of this disclaimer is attached.

Undersigned further declares that the evidentiary documents establishing ownership by the assignee have been reviewed and certifies that to the best of assignee's knowledge and belief, title is in the assignee seeking to take this action.

Undersigned further declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: November 22, 2004

By: 

Wei-Ning Yang
Reg. No. 38,690
Attorney for Applicant and Assignee

HOGAN & HARTSON L.L.P.
Biltmore Tower
500 South Grand Avenue, Suite 1900
Los Angeles, CA 90071
Telephone: (213) 337-6700
Facsimile: (213) 337-6701